Evidence map›Paper›PMID 41175001›Full record

ArticleTransfusion2025

Evaluation of peripheral blood stem cell collection in the Japan Marrow Donor Program (JMDP).

Rie Yamazaki, Kimikazu Yakushijin, Satoshi Yoshihara, Kazuhiko Ikeda, Akaru Ishida, Michiko Kajiwara, Atsushi Kikuta, Naoe Takagi, Tokiko Nagamura-Inoue, Noriko Namba and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rie YamazakiCenter for Transfusion Medicine and Cell Therapy, Keio University Hospital, Shinjuku-ku, Japan.ORCID https://orcid.org/0000-0001-7489-4180
Kimikazu YakushijinDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan.
Satoshi YoshiharaDepartment of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan.
Kazuhiko IkedaDepartment of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan.
Akaru IshidaDivision of Transfusion Medicine and Cell Transplantation, Saitama Medical University International Medical Center, Hidaka, Japan.
Michiko KajiwaraCenter for Transfusion Medicine and Cell Therapy, Institute of Science Tokyo Hospital, Bunkyo-ku, Japan.
Atsushi KikutaDepartment of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.
Naoe TakagiDivision of Nursing, Okayama University Hospital, Okayama, Japan.
Tokiko Nagamura-InoueDepartment of Cell Processing and Transfusion, The Institute of Medical Science, The University of Tokyo, Minato-ku, Japan.
Noriko NambaOperations Promotion Department, Section 2, Japanese Red Cross Tokyo Metropolitan Blood Center, Shinjuku-ku, Japan.
Kyoko HaraguchiDivision of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Japan.
Yoshiaki FujimoriDepartment of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan.
Shin-Ichiro FujiwaraDivision of Cell Transplantation and Transfusion, Jichi Medical University Hospital, Shimotsuke, Japan.ORCID https://orcid.org/0000-0002-4523-2994
Minami Yamada-FujiwaraDivision of Blood Transfusion and Cell Therapy, Tohoku University Hospital, Sendai, Japan.
Yoshiki OkuyamaDivision of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Japan.
Ryuji TanosakiCenter for Transfusion Medicine and Cell Therapy, Keio University Hospital, Shinjuku-ku, Japan.
Yasunori UedaDepartment of Hematology/Oncology Transfusion and Hemapheresis Center, Kurashiki Central Hospital, Kurashiki, Japan.ORCID https://orcid.org/0000-0002-4487-5808

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor peripheral blood stem cell (PBSC) collection of unrelated donors, the Japan Marrow Donor Program (JMDP) sets the target CD34+ cell dose as the minimum of 2 × 10 STUDY DESIGN AND

methodsWe analyzed 1656 unrelated donor PBSC collections between January 2012 and November 2022 from the JMDP database.

resultsThe target CD34+ cell dose was achieved within 2 days in all but 40 cases (2.4%), suggesting that the current JMDP guideline largely meets its objectives. The distribution of PBV per DBW showed three peaks. The most prominent peak, consisting of 834 (50.4%) cases, occurred around the recommended PBV (180-220 mL/kg of DBW), whereas 659 (39.8%) cases were in the lower PBV range (<180 mL/kg), and, notably, there was no significant difference between these groups in the collected CD34+ cells/kg RBW. On the other hand, among the 163 (9.8%) cases in the higher PBV group (>220 mL/kg), the number of collected CD34+ cells/kg of RBW was significantly lower than in the other two groups. DISCUSSION: These results suggest that the target PBV in the lower and higher PBV groups was determined using CD34+ enumeration before or during apheresis procedure. CD34+ enumeration may help reduce the burden on donors, although further investigations are needed to confirm.

Indexed as

Peripheral Blood Stem CellsAdultAntigens, CD34FemaleHumansJapanMaleMiddle AgedRetrospective StudiesUnrelated DonorsAntigens, CD34apheresisCD34 positive cellflow cytometryJapan Marrow Donor Program (JMDP)peripheral blood stem cell collection

Identifiers

PMID41175001
PMCPMC12704693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.